Edwards Lifesciences Reports First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Edwards Lifesciences (EW) PT Raised to $105 at Piper Sandler
April 21, 2021 9:22 AM EDTPiper Sandler analyst Adam Maeder raised the price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $97.00) while maintaining a Overweight rating.
... MoreEdwards Lifesciences (EW) PT Raised to $103 at Canaccord Genuity
April 21, 2021 8:26 AM EDTCanaccord Genuity analyst Jason Mills raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $94.00) while maintaining a Buy rating.
The analyst commented, "EW Q1/21 revenue of $1,217M (+7.8% GAAP Y/Y; +5.0% adjusted CC),beat our estimate of $1,176M and consensus of $1,162M. There was positive Y/Y growth from... More
Edwards Lifesciences (EW) PT Raised to $103 at Stifel
April 21, 2021 8:16 AM EDTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "Overall, Edwards better-than-expected 1Q21 results marked a solid start to 2021, and post-release recovery trend/guidance commentary left us feeling... More
Edwards Lifesciences (EW) PT Raised to $110 at Jefferies
April 21, 2021 8:09 AM EDTJefferies analyst Raj Denhoy raised the price target on Edwards Lifesciences (NYSE: EW) to $110.00 (from $105.00) while maintaining a Buy rating.
The analyst commented, "EW posted $60mn/$0.07 beat with US TAVR flat offset by a rebound OUS to low DDs(HSD in... More
Edwards Lifesciences (EW) Tops Q1 EPS by 6c, Revenues Beat; Offers FY21 EPS Outlook
April 20, 2021 4:17 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.54, $0.06 better than the analyst estimate of $0.48. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.16 billion.
First Quarter Highlights and 2021 Outlook
Sales grew 8 percent to $1.2 billion; underlying1 sales grew 5 percentTAVR sales grew 7 percent; underlying sales... More